{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:35:46Z","timestamp":1793900146765,"version":"4.8.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1001\/jamaoncol.2018.3039","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T13:59:57Z","timestamp":1533823197000},"page":"1569","source":"Crossref","is-referenced-by-count":534,"title":["Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"4","author":[{"given":"Baohui","family":"Han","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Linyi Cancer Hospital, Linyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine-Oncology, Shandong Cancer Hospital, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhuo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Lanzhou Military General Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pirker","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Nan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faguang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Tang Du Hospital, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Dong","sequence":"additional","affiliation":[{"name":"First Department of Medical Oncology, Yunnan Cancer Hospital, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Capital Medical University, Beijing Chest Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"coi180061r1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"2","key":"coi180061r2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015.","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"coi180061r3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.v66.4","article-title":"Cancer treatment and survivorship statistics, 2016.","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"coi180061r4","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1517\/14656566.2010.511615","article-title":"Advances in chemotherapy in advanced non-small-cell lung cancer.","volume":"11","author":"Maione","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"coi180061r5","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.","volume":"4","author":"Chan","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"18","key":"coi180061r6","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non\u2013Small Cell Lung Cancer: the SELECT-1 randomized clinical trial.","volume":"317","author":"J\u00e4nne","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"coi180061r7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"coi180061r8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u00df and FGFR1.","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"issue":"1","key":"coi180061r9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/IGC.0000000000001129","article-title":"Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model.","volume":"28","author":"Taurin","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"coi180061r10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","article-title":"Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).","volume":"118","author":"Han","year":"2018","journal-title":"Br J Cancer"},{"issue":"20","key":"coi180061r11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"9944","key":"coi180061r12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"coi180061r13","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi180061r14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0169-5002(02)00308-2","article-title":"A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.","volume":"39","author":"Massarelli","year":"2003","journal-title":"Lung Cancer"},{"issue":"2","key":"coi180061r15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non\u2013small cell lung carcinoma: a systematic review and meta-analysis.","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"coi180061r16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi180061r17","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1097\/JTO.0000000000000693","article-title":"Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) trial: a phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens.","volume":"10","author":"Paz-Ares","year":"2015","journal-title":"J Thorac Oncol"},{"key":"coi180061r18","doi-asserted-by":"publisher","first-page":"ixe1","DOI":"10.1093\/annonc\/mds499","article-title":"Association between tumor EGFR and KRAS mutation status and clinical outcomes in NSCLC patients randomized to sorafenib plus best supportive care (BSC) or BSC alone: subanalysis of the phase III MISSION trial.","volume":"23","author":"Mok","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"coi180061r19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ctrv.2015.04.011","article-title":"FGFR as potential target in the treatment of squamous non small cell lung cancer.","volume":"41","author":"Tiseo","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"coi180061r20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.","volume":"34","author":"Helsten","year":"2015","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"coi180061r21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/ncb3228","article-title":"Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation.","volume":"17","author":"Procopio","year":"2015","journal-title":"Nat Cell Biol"},{"issue":"33","key":"coi180061r22","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1200\/JCO.2008.17.3138","article-title":"Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.","volume":"26","author":"Heymach","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi180061r23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40265-015-0434-6","article-title":"Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK.","volume":"75","author":"Califano","year":"2015","journal-title":"Drugs"},{"issue":"3","key":"coi180061r24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000262450","article-title":"Antiangiogenic drugs in oncology: a focus on drug safety and the elderly\u2014a mini-review.","volume":"56","author":"Boehm","year":"2010","journal-title":"Gerontology"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2696341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T11:02:29Z","timestamp":1541674949000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.3039"}},"subtitle":["The ALTER 0303 Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.3039","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}